Professor of Hematology and Oncology, University Iowa College of Medicine
Hematology
Dr. Brian K. Link, MD
|
|
Give Review
Brian Link practices Hematology. He went to University of Iowa Carver College of Medicine. University of Iowa Carver College of Medicine has a rank of 29 in research and a 16 in primary care He received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Dr. Brian K. Link has written publications. He has 78 publications published with PubMed. The lastest paper is: 'Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes.' Brian Link accepts all Medicare patients.
Publications
- Outcomes following watchful waiting for stage II-IV follicular Lymphoma patients in the modern era.
- Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
- Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an Analysis from the National Lymphocare Study†.
- Personalized risk prediction for event-free survival at 24 months in patients with diffuse large b-Cell lymphoma.
- Isolated unilateral facial nerve palsy: an unusual manifestation of recurrent diffuse large B-Cell lymphoma.
- Reply to V. Pitini et al and L.J. Costa.
- Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following inDuction chemotherapy for previou...
- Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular Lymphoma in the immunochemotherapy era: a report from the University of Iowa...
- Treatment of diffuse large B-Cell lymphoma in the elderly: regimens without anthracyclines are common and not futile.
- Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-Cell non-Hodgkin lymphoma.
- Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular Lymphoma.
- Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular Lymphoma used in the United States.
- Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region.
- Genome-wide association study identifies multiple susceptibility loci for diffuse large B Cell lymphoma.
- Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic Leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab ...
- Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma.
- Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma.
- Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-Cell lymphoma.
- Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-Cell non-Hodgkin lymphoma.
- The use and effectiveness of rituximab maintenance in patients with follicular Lymphoma diagnosed between 2004 and 2007 in the United States.
- Reassessing imaging surveillance in diffuse large B-Cell lymphoma.
- Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma.
- Unmet needs in mantle Cell lymphoma: general discussion.
- Current treatment approaches to mantle Cell lymphoma.
- Patterns of delivery of chemoimmunotherapy to patients with follicular Lymphoma in the United States: Results of the National LymphoCare Study.
- Cytokine gene polymorphisms and progression-free survival in classical Hodgkin Lymphoma by EBV status: Results from two independent cohorts.
- Genome-wide association study identifies multiple risk loci for chronic lymphocytic Leukemia.
- Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Researc...
- CXCR5 polymorphisms in non-Hodgkin Lymphoma risk and prognosis.
- Papular mycosis fungoides: report of two patients, literature review, and conceptual re-appraisal.
- A phase i trial of immunostimulatory CpG 7909 oligodeoxynucleotide and (90) yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-Cell non-hodgkin lymphoma.
- Mapping of the IRF8 Gene Identifies a 3'UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes.
- The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma.
- Examination of the follicular Lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predomin...
- Chemo-immunotherapy dosing in older patients with diff use large B-Cell lymphoma: is this how we should treat our parents?
- A Phase 1 Study of AME-133v (LY2469298) an Fc-Engineered Humanized Monoclonal Antibody in Fc?RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma.
- Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin Lymphoma.
- A genome-wide meta-Analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32.
- A Phase I Clinical Trial of CpG Oligonucleotide 7909 (PF-03512676) in Patients with Previously Treated Chronic Lymphocytic Leukemia.
- Rituximab infusion induces NK activation in Lymphoma patients with the high affinity CD16 polymorphism.
- Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic Leukemia.
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory Lymphomas.
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cel...
- Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-Cell lymphoma: a series of 10 adult and pediatric patients and review of the li...
- Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-Cell lymphoma.
- Diffuse large B-Cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines.
- Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.
- Vitamin D insufficiency and prognosis in chronic lymphocytic Leukemia.
- Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma.
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-Cell lymphoma.
- Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic Leukemia: final anal...
- Vitamin D insufficiency and prognosis in non-Hodgkin's Lymphoma.
- Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular Lymphoma: eight-year f...
- Follicular Lymphoma in the United States: first report of the national LymphoCare study.
- Measuring granulocyte and monocyte accumulation at malignant Lymphoma sites.
- Optimizing chemotherapeutic strategies for peripheral T-Cell lymphomas.
- A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular Lymphoma.
- Imaging guiding therapy development in Lymphoma.
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular Lymphoma: results of a phase 1/2 trial.
- Monoclonal antibodies in Lymphoma: the first decade.
- Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's Lymphoma.
- Do recent reports of prolonged survival in patients with follicular Lymphoma suggest that deferral of therapy is no longer justifiable?
- Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK Cells at lower concentrations and more effectively than rituximab.
- Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin Lymphoma.
- Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate Cancer.
- Improved survival of follicular Lymphoma patients in the United States.
- Response assessment of aggressive non-Hodgkin's Lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
- Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's Lymphoma cases during first-course chemotherapy.
- Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic Leukemia cells.
- Optic neuropathy due to anaplastic large Cell lymphoma.
- Antibody therapy of Lymphoma.
- Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's Lymphoma.
- Post-treatment surveillance of patients with Lymphoma treated with curative intent.
- Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's Lymphoma treated with chemotherapy.
- Immunotherapy of non-Hodgkin's Lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
- Identification of candidate B-Lymphoma genes by cross-species gene expression profiling.
- Genetically predicted longer telomere length is associated with increased risk of B-Cell lymphoma subtypes.
Schools
University of Ia Roy J amp L Carver Com
Rush Presby St Lukes Med Ct
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Iowa Hospitals and Clinics -
Rush University Medical Center -
University of Iowa Carver College of Medicine
Drug Facts
| NPI NUMBER | 1487635793 | |
| NPPES Provider LastName | LINK | |
| NPPES Provider FirstName | BRIAN | |
| NPPES Provider ZIPCode | 522421009 | |
| NPPES Provider State | IA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 100.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487635793 |
| Last Name Of The Provider | LINK |
| First Name Of The Provider | BRIAN |
| View All |
Similar Doctors
|
|
Dr. Yousef Zakharia, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thorvardur R. Halfdanarson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah A. Holstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lori J. Rosenstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel A. Vaena, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Usha S. Perepu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam M. Bell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Guido Tricot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katarzyna J. Jamieson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wenshuo Shao, MD |
|
|
Dr. Jeremy Deutsch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chinemerem F. Abanonu, MD |